Cassava Sciences Inc (SAVA NASDAQ) stock market data APIs
$2.1036
0.04(1.9%)
as of September 12, 2025
Try our APIs with
free plan!
Cassava Sciences Inc Financial Data Overview
Price chart is built with
Anychart
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
Prev. Close
2.1036
Open
2.1476
High
2.1483
Low
2.0774
52 wk Range
1.15-33.98
Market Cap
102 M
Shares Outstanding
48 308 K
EPS
-0.92
Beta
-2.068
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Cassava Sciences Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Cassava Sciences Inc data using free add-ons & libraries
Get Cassava Sciences Inc Fundamental Data
Cassava Sciences Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -89 031 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-14
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cassava Sciences Inc News
New
Prediction: This Quantum Computing Stock Will Still Be Worth More Than Berkshire Hathaway, Palantir, and Tesla Combined in 2030
Key Points Nvidia is the most valuable company in the world by market cap. Its unique blend of hardware and software positions it as an indispensable technology stack provider for all things touching...
Cassava Sciences GAAP EPS of -$0.92
* Cassava Sciences press release [https://seekingalpha.com/pr/20200807-cassava-reports-q2-2025-financials-results-and-provides-business-update] (NASDAQ:SAVA [https://seekingalpha.com/symbol/SAVA]): ...
Cassava Reports Q2 2025 Financials Results and Provides Business Update
Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyRecent appointment of experi...
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer
Joseph Hulihan, MD, MSHP, brings substantial clinical development experience advancing novel therapies for TSC-related epilepsy and other neurological disordersClinical study for simufilam in TSC-rela...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
